Sebolox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sebolox

Property Description
Active Ingredient Miconazole Nitrate
Form Medicated shampoo, topical solution, or foam
Pharmacological Class Azole Antifungal / Imidazole Derivative
General Purpose Addresses superficial fungal infections
Origin Synthetic Compound

What Type of Medicine is Sebolox and Its Primary Component?

Sebolox is identified as a topical antimycotic preparation, a medicine designed for localized application to the skin or scalp. Its sole active ingredient is Miconazole Nitrate (INN). The compound belongs to the imidazole class of azole antifungals, distinguishing it pharmacologically from older types of topical treatments. Miconazole is a synthetic derivative that is clinically recognized for its effectiveness against a broad spectrum of fungal pathogens. Sebolox is often positioned specifically for patients dealing with scalp conditions, where the shampoo formulation provides a convenient application method.

The Role and General Benefit of an Imidazole Antifungal

The primary functional role of Miconazole Nitrate is to control and neutralize the underlying fungal overgrowth on the surface of the body. This synthetic azole achieves its effect by disrupting the structural integrity of the fungal cell membrane, which is essential for the organism's survival. The specific mechanism involves inhibiting the synthesis of ergosterol, a crucial fungal cell component. Miconazole is characterized by broad-spectrum activity against various yeasts and dermatophytes prevalent in superficial mycoses. This medicine works directly to address the source of the fungal issue.

Sebolox Dosage Forms and Route of Application

Sebolox is consistently formulated as a product intended for topical application to the dermal layers, most commonly supplied as a medicated shampoo, solution, or foam. This dosage form is strategically designed to deliver a high local concentration of Miconazole Nitrate directly to the affected site. This external route of administration is specifically chosen for superficial infections because very little of the drug is absorbed into the systemic circulation, allowing the medicine to efficiently target the fungal colonies where the infection is localized while minimizing the body's overall exposure to the drug.

What side effects are possible with Sebolox?

Possible Side Effects and Safety Information

The safety profile for Sebolox, which contains the active ingredient Miconazole Nitrate, is based on its primary function as a topical medication with minimal systemic absorption. Adverse reactions are primarily localized, meaning they occur at the site of application. These effects are officially grouped under the Skin and Subcutaneous Tissue Disorders and General disorders and administration site conditions categories in regulatory documents.

Frequency-Classified Adverse Reactions

The incidence of adverse effects is formally classified according to regulatory standards (e.g., CIOMS frequency bands):

Classification Example Reactions (System-Organ Class)
Common (ge 1/100 to < 1/10) Burning sensation (at the application site)
Uncommon (ge 1/1,000 to < 1/100) Pruritus (itching), Erythema (redness), Skin irritation
Not Known Urticaria (hives), Contact dermatitis, Application site swelling

Safety Considerations and Constraints

The most commonly reported local reactions, such as the burning sensation and irritation, are often noted to occur at the beginning of treatment or immediately following application. The potential for rare but serious adverse reactions is documented under Immune System Disorders; this includes the potential for severe Hypersensitivity and Anaphylactic Reaction.

Sebolox is strictly for external use only. A key regulatory constraint is the absolute contraindication against its use in individuals with a known hypersensitivity to Miconazole Nitrate or any of the product's excipients. Due to the negligible systemic absorption from the topical route, regulatory documents do not typically mandate specific risk adjustments for populations with renal or hepatic impairment.

Overdose and Emergency Response

Sebolox Overdose and When to Seek Help

The official regulatory documents for Miconazole Nitrate topical define overdose based on the route of exposure, noting that severe systemic toxicity is not reported due to the medication’s minimal absorption through the skin.

Documented Overdose Manifestations

Exposure Scenario Clinical Presentation (as documented)
Accidental Oral Ingestion Gastrointestinal effects, including nausea and vomiting, and stomach irritation.
Excessive Cutaneous Use Local dermal reactions, such as skin irritation, redness, and a burning sensation at the site of application.

Emergency Actions and Required Care

In the event of known or suspected accidental oral ingestion of the topical product, regulatory authorities mandate that professional assistance be sought or a Poison Control Center contacted immediately.

Management of overdose is symptomatic and supportive, as official labeling confirms that no specific antidote is known for Miconazole Nitrate. Procedural steps such as gastric lavage (stomach emptying) may be considered by medical personnel following the ingestion of substantial amounts. Immediate medical attention is not typically required for symptoms resulting solely from excessive topical application, as these effects resolve after discontinuation.

Therapeutic Uses of Sebolox

What Sebolox Treats: Main Uses and Benefits

Sebolox is commonly used to provide symptomatic relief and management for a range of localized fungal and yeast infections. The medication is generally used in situations involving certain distressing symptoms across multiple dermatological domains.

Sebolox is applied across domains where additional symptomatic support is needed for conditions such as Athlete's Foot (Tinea pedis), Jock Itch (Tinea cruris), Ringworm (Tinea corporis), and cutaneous candidiasis. It helps address symptom clusters that may become intense or disruptive, such as persistent itching, a burning sensation, redness, and the peeling or cracking of the skin. This use is relevant for easing symptoms related to inflammatory or irritative states, assisting with maintaining functional stability.

The medication's application supports the patient during difficult episodes by easing distress, generally providing support that helps ease the overall symptom burden. The core benefit is applied in addressing conditions marked by increased physiological stress.

“The treatment supports the patient during episodes of heightened discomfort by controlling the infection.”


Quick Fact: Relief for Fungal Skin Discomfort Sebolox is applied in scenarios where additional management of discomfort is required for conditions characterized by periods of heightened symptoms, generally assisting with maintaining skin integrity and contributing to easing the overall symptom load.

Regulatory References

  1. FDA DailyMed Overview on Miconazole Nitrate

Eligibility and Restrictions for Use

Who Can and Cannot Use Sebolox? (Official Regulatory Information)

Sebolox (topical Miconazole Nitrate) eligibility is defined by regulatory criteria focusing on patient status, age, and co-medication. The medicine is absolutely contraindicated in individuals with a known hypersensitivity or allergy to miconazole, other imidazole derivatives, or any non-active ingredients within the specific formulation.

Age-Related Eligibility

Age Group Eligibility Status (Regulatory Basis)
Adults Established for use for labeled superficial fungal infections.
Children Safety and effectiveness are established for those 2 years of age and older. Use is not recommended in pediatric patients under 2 years unless directed by a physician.
Infants Use is not established for infants under 4 weeks of age and very-low-birth-weight infants for certain formulations.

Conditional Use and Restrictions

Use requires caution in specific patient populations. Patients currently receiving systemic anticoagulants (e.g., Warfarin) must have their anticoagulant effect monitored due to the potential for interaction, despite minimal systemic absorption. Regulators advise the medicine be used with caution during pregnancy and lactation, as it is not known if Miconazole is excreted in human breast milk. No explicit restrictions are documented for renal or hepatic impairment due to its topical route of administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sebolox contains Miconazole Nitrate, an active ingredient whose interaction profile is derived from its potential to inhibit certain liver enzymes. Due to the medicine's topical application as a shampoo, solution, or foam, the systemic absorption is minimal, making clinically significant interactions rare. However, regulatory agencies formally document one specific interaction risk related to Miconazole's ability to inhibit Cytochrome P450 (CYP) enzymes, specifically CYP2C9 and CYP3A4.


Official Regulatory Interaction Profile

Classification Interacting Substances Outcome and Constraint
Pharmacokinetic Risk Oral Anticoagulants (e.g., Warfarin, Acenocoumarol) Co-administration may enhance the anticoagulant effect, potentially leading to increased International Normalized Ratio (INR) and bleeding.
Required Constraint Patients on oral anticoagulants The official prescribing information requires close monitoring of the anticoagulant effect (INR or prothrombin time) when Sebolox is co-administered.

No mandatory restrictions are documented for co-administration with food, alcohol, or herbal products. Furthermore, no specific drug-drug combination is formally classified as contraindicated for the topical formulation, and no mandatory timing separation rules are required.

Mechanism of Action

Miconazole Nitrate exerts its effect through a selective, dual-action mechanism that targets systems unique to the fungal cell, resulting in fungal cell necrosis and lysis. The action is localized to the site of application with negligible systemic absorption.

Inhibiting Fungal Ergosterol Biosynthesis

The primary action involves the inhibition of the fungal enzyme Lanosterol 14-alpha demethylase ( CYP51). This enzyme is crucial for synthesizing ergosterol, a key structural lipid in the fungal cell membrane. By blocking this step, the drug depletes ergosterol while causing the buildup of toxic sterol precursors, such as lanosterol, which initiates the impairment of fungal cell membrane integrity.

Direct Cell Membrane Damage and Oxidative Stress

Miconazole achieves its fungicidal action through a second, independent mechanism: direct destabilization of the fungal cell membrane's phospholipid bilayer. Concurrently, the molecule interferes with the fungus’s defensive enzymes, resulting in the rapid intracellular accumulation of toxic Reactive Oxygen Species (ROS). This dual attack of membrane disruption and internal toxicity severely compromises the cell, leading to membrane lysis and ultimate fungal cell death.

Dosage and Administration Information

Sebolox is a topical preparation used according to specific administration protocols. The instructions define how the medicine is applied and for what duration, focusing exclusively on procedural adherence without detailing therapeutic outcomes or safety considerations.

Administration Scope

Component Official Rule
Route of administration: Topical (Cutaneous use) only.
Dosing schedule: A thin layer of the product is applied to cover the entire affected area and the immediate surrounding skin.
Timing in relation to meals: Not applicable, as it is a topical preparation.
Preparation requirements: The affected skin area must be cleaned and thoroughly dried before each application.
Age-group administration rules: Children under 2 years of age must not use the product unless under the advice and supervision of a physician.
Missed-dose rules: Not explicitly detailed in general labeling; consistency in daily application is emphasized.
Special procedural conditions: Must be used for external use only. The preparation must be gently rubbed into the skin until fully absorbed.

Instruction Classifications (High-Level)

Classification Description
Administration method type: Topical application.
Frequency pattern: Daily (Twice daily or Once daily, depending on the specific condition).
Use-context constraints: Applied for a specific, mandated duration (e.g., 2 or 4 weeks) and continued until the full treatment course is completed.

Resulting Procedural Structure

Official step sequence:

  • Clean the affected skin area and dry it thoroughly.
  • Apply a thin layer of Sebolox to cover the entire affected area and the surrounding healthy skin.
  • Gently rub the preparation into the skin until it is fully absorbed.
  • Repeat the application, typically twice daily, for the specified course duration.

Connection to the overall use protocol (3 sentences): The official instructions establish a standardized administration protocol centered on a defined topical route and a fixed daily frequency. This protocol mandates specific preparation steps and sets a required treatment duration, which collectively structures the necessary adherence for completing the official course. The guidelines specify the precise dose amount and application technique without providing interpretation of clinical outcomes.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Mechanism of Action

Research has examined how the drug may affect the body. Research explored the drug's action and reported findings related to certain nervous system receptors. The research investigated the possibility that this action may influence the transmission of signals.

Efficacy and Outcome Measures

Research has explored whether this approach has therapeutic potential. Studies investigated whether it is associated with differences in outcomes for people experiencing acute and chronic pain.

  • Acute Pain: A randomized, controlled trial (RCT) with 450 participants focused on post-surgical discomfort. Researchers reported a measured difference in the change in reported pain scores for participants in the active treatment group compared to the placebo group.
  • Chronic Pain: The largest study, involving 8,000 participants, reported an association with change in symptoms and suggested a difference in the perception of discomfort for many participants.

Safety and Tolerability Profile

Studies explored the drug’s potential to affect the perception of discomfort, examining whether it influences the body's natural response.

Studies recorded observations such as mild headache, fatigue, and dizziness. In some research, participants reported differences in discomfort perception within 48 hours.

Combination Use and Complex Cases

Multiple smaller-scale studies have explored the potential use of this drug in combination with other existing treatments. For example, in a study of 50 participants, studies examined whether the combination was associated with differences in the outcome measure when administered alongside a non-steroidal anti-inflammatory drug (NSAID).

  • Special Populations: Researchers also explored its use in complex cases, such as neuropathic discomfort where traditional treatments had limited impact.
  • Safety Explorations: Safety explorations included studies where participants reported on effects such as potential driving impairment. Other exploratory studies focused on interactions with common over-the-counter medications.

Frequently Asked Questions (FAQ)

Common questions about Sebolox (FAQ)


Q: What is the main reason people are prescribed Sebolox?

A: Official regulatory documentation describes the medicine's approved purpose as the topical treatment of various fungal skin infections. This includes common conditions like athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).

Q: How quickly does Sebolox usually start to work?

A: Official guidance on use duration suggests that if no improvement is noted within the prescribed time, typically 2 to 4 weeks depending on the specific condition, consultation with a healthcare provider is appropriate. Some clinical studies focusing on related effects have observed differences in the perception of discomfort within 48 hours.

Q: How long does Sebolox stay in my system after the last dose?

A: The topical formulation is designed to have minimal systemic absorption, which means that only very small amounts of the active ingredient are expected to enter the bloodstream. The drug's action is highly localized to the application site.

Q: What are the typical expected outcomes described in the studies for Sebolox?

A: Research reviewed in official documents has explored whether the medicine is associated with differences in patient experiences. Studies have reported that it is associated with measured differences in reported pain scores in acute pain and an association with changes in symptoms and perception of discomfort in chronic pain.

Q: Why is Sebolox sometimes mentioned in discussions about chronic conditions?

A: Official research evidence notes that the drug’s potential was investigated in complex cases, including a large study focusing on chronic pain. This study reported an association with change in symptoms for many participants who were experiencing long-term discomfort.

Q: Is Sebolox safe for people with a history of kidney issues?

A: Because of the minimal systemic absorption from the skin surface, regulatory documents generally indicate that specific dose adjustments are not required for populations with renal (kidney) impairment.

Q: Is Sebolox safe for people who have liver problems?

A: Because the medicine is applied topically and has minimal systemic absorption, official regulatory documents generally indicate that specific dose adjustments are not required for populations with hepatic (liver) impairment.

Q: Can women who are planning to become pregnant use Sebolox?

A: The medicine has not been officially assigned an FDA Pregnancy Category. According to regulatory information, use is generally considered only when alternatives are unavailable and the potential benefit is assessed to justify any potential risk. Minimal systemic absorption is noted.

Q: Can men use Sebolox if they are trying to conceive a child?

A: Regulatory-sourced information and studies on the topical formulation of the active ingredient have not specifically assessed whether it affects male fertility or increases general background risks to a pregnancy.

Q: Is Sebolox ever used for conditions other than its main approved use?

A: Official regulatory documents define the medicine's use strictly for its approved indications, which are the treatment of specified fungal skin infections. Regulatory documents solely define and support the medicine's use for these approved indications.

Q: Is Sebolox considered a controlled substance?

A: The active ingredient in Sebolox, Miconazole, is classified as Not a controlled drug by regulatory agencies. It is generally available as an over-the-counter (OTC) product in many markets.

Q: Is there any risk of becoming dependent on Sebolox?

A: Since the medicine is not a controlled substance and has minimal systemic absorption, official regulatory documents do not list dependence potential as a known risk associated with its use.

Q: Does Sebolox interact with herbal supplements like St. John's Wort?

A: Regulatory advisories suggest that topical medicines with limited systemic absorption are generally not likely to interact significantly with supplements like St. John’s Wort, which primarily interacts with systemic medications via liver enzymes.

Q: Does Sebolox affect blood pressure or heart rate?

A: Adverse reactions listed in regulatory documents are primarily localized skin reactions (such as burning or irritation). Systemic effects like changes in blood pressure or heart rate are not documented as Common or Uncommon Adverse Reactions in the regulatory safety profile.

Q: What happens if Sebolox is taken with alcohol?

A: Regulatory documents explicitly state that no mandatory restrictions are documented for co-administration with alcohol when using the topical preparation.

Q: Can teenagers or children take Sebolox?

A: Official prescribing information describes its use for adults and children age 2 and older. However, the official prescribing information states that it is contraindicated (not allowed) for children under 2 years of age unless specifically directed by a healthcare provider.

Q: Is Sebolox available in different forms, like a tablet and a liquid?

A: The medicine is available in several topical dosage forms, including a cream, ointment, lotion, aerosol spray, and powder. The approved route of administration is strictly external (cutaneous) use.

Q: Does Sebolox interfere with the effectiveness of birth control pills?

A: Broad-spectrum antifungals are typically classified as having no restriction for use with combined hormonal contraceptives. Consultation with a healthcare provider remains a standard recommendation for any new medication.

Q: What if I'm already taking medicine for depression or anxiety—is Sebolox safe?

A: Regulatory documents list a pharmacokinetic interaction risk primarily with oral anticoagulants (like Warfarin) due to enzyme inhibition. Interactions with psychiatric medications are not typically cited as a contraindication risk for this topical formulation.

Q: Why are people often told to take Sebolox with a meal?

A: As a topical preparation, the question of whether to take the medicine with a meal is not applicable to its administration instructions. The instructions relate only to cleaning and drying the skin before external application.

Q: Is it normal for my urine color to change while on Sebolox?

A: Changes in urine color are not listed as a documented adverse reaction (Common, Uncommon, or Not Known frequency) in the official safety profile for this medicine.

Q: Is Sebolox used worldwide, or only in certain countries?

A: The active ingredient in Sebolox is a globally recognized and registered substance that has been approved for human use in the United States, Europe, and many other international markets since the 1970s.

Q: Can taking Sebolox cause problems with sleep?

A: Clinical studies have noted observations of fatigue and dizziness in participants. These are systemic effects that may indirectly influence the ability to sleep, but specific sleep disorders are not listed as common adverse reactions.

Q: Is there a generic version of Sebolox available?

A: The active ingredient is a widely available compound that is often sold in the US and internationally under generic formulations and various brand names.

How should Sebolox be stored and disposed of?

Sebolox (Miconazole Nitrate topical) must be stored at Controlled Room Temperature, specifically between 15 C and 30 C (59 F to 86 F). It is essential to keep the product from freezing and to avoid heat above the maximum specified temperature. The medication must be kept in a closed container, and the storage environment should offer protection from light and moisture.

Requirement Condition
Temperature 15 C to 30 C
Protection Keep from freezing, light, and moisture

All medicine must be kept out of the reach of children.

Regarding disposal, users must not keep outdated medicine or medicine no longer needed. Used applicators for certain forms must be thrown away in the trash and not flushed into the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sebolox found in:

A-Z Index: